FDA Grants Minor Use Designation to Endovia’s CannEpil for Canine Bone Cancer

Key Facts

1The US FDA determined that CannEpil qualifies as a 'minor use' for controlling bone cancer pain in dogs.

2This designation establishes eligibility for a conditional approval pathway under the MUMS program for Endovia.

The US FDA determined that CannEpil, an oral solution developed by Endovia Health Sciences, qualifies as a 'minor use' for controlling bone cancer pain in dogs. GlobeNewswire reported that this designation establishes the company's eligibility for a conditional approval pathway under the Minor Use and Minor Species (MUMS) program.

EDVA closed at $0.1594 on October 2, 2026, with the stock reaching a day high of $0.16425 and a low of $0.1515. This regulatory milestone is part of the company's collaboration with Lupvindol BioSciences to advance cannabinoid-based treatments for the veterinary sector.

Endovia is scheduled to hold a formal pre-submission conference with the FDA on November 19, 2026, to align on the development program and manufacturing requirements for the drug's conditional approval.